Cytomegalovirus gB Antibody [CoraFluor™ 1]
Novus Biologicals, part of Bio-Techne | Catalog # NBP3-06076CL1
Conjugate
Catalog #
Forumulation
Catalog #
Key Product Details
Species Reactivity
Cytomegalovirus
Applications
ELISA
Label
CoraFluor 1
Antibody Source
Polyclonal Rabbit IgG
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Specifications
Immunogen
Produced in rabbits immunized with purified, recombinant Human Cytomegalovirus gB (Accession#: AAA45920.1) extracellular domain (Met 1-Lys 700) linked with the cytoplasmic domain (Arg 777-Val 907)
Clonality
Polyclonal
Host
Rabbit
Isotype
IgG
Description
This conjugate is made on demand and is not held in inventory. Each order represents a unique lot. All conjugates are generated using validated conjugation protocols and meet strict degree of labeling (F/P) specifications; additional information is available upon request. The antibody concentration is provided on the individual product label.
For specialized conjugation needs, like large quantities, specific concentrations, and defined F/P ratios, bulk and custom antibody conjugation services are available.
For specialized conjugation needs, like large quantities, specific concentrations, and defined F/P ratios, bulk and custom antibody conjugation services are available.
Scientific Data Images for Cytomegalovirus gB Antibody [CoraFluor™ 1]
Product Feature: CoraFluor Probes for TR-FRET
CoraFluor™ 1, amine reactive (Catalog:7920) and CoraFluor™ 2, amine reactive (Catalog # 7950) are terbium-based probes that have been developed for use as TR-FRET donors. They emit wavelengths compatible with commonly used fluorescent acceptor dyes such as BODIPY® (or BDY) and Janelia Fluor® dyes, FITC (Catalog # 5440), TMR and Cyanine 5 (Catalog # 5436). CoraFluor™ fluorescence is brighter and more stable in biological media than existing TR-FRET donors, leading to enhanced sensitivity and improved data generation. CoraFluor™ 1 exhibits excitation upon exposure to a 337 nm UV laser.Applications for Cytomegalovirus gB Antibody [CoraFluor™ 1]
Application
Recommended Usage
ELISA
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Recommended applications are based on validated applications from the unconjugated base product NBP3-06076. This conjugated antibody is not kept in inventory and is made to order using validated conjugation protocols.
Formulation, Preparation, and Storage
Purification
Antigen and protein A Affinity-purified
Formulation
PBS
Preservative
No Preservative
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark. Do not freeze.
Background: Cytomegalovirus gB
Cytomegalovirus is a common virus, infecting ~60% of adults in developed countries and over 90% in developing countries, as indicated by presence of specific IgG antibodies (2-4). Although a majority of people infected remain asymptomatic, immunocompromised people, organ transplant recipients, and fetuses and newborns are more susceptible to HCMV-associated diseases (1-4). Annually, up to 2% of newborns are born with HCMV, making it the most common congenital infection (2-4). Cytomegalovirus is known to cause sensorineural hearing loss (SNHL), mental retardation, chorioretinitis, skin lesions, as well as end organ disease (3,5). There are a few CMV therapeutics approved by FDA including valganciclovir and letermovir; however, despite some benefits, there is the need for new antivirals and combination therapies (5). Potential new treatment options include monoclonal antibodies and sirtuins (5).
References
1. Connolly SA, Jardetzky TS, Longnecker R. The structural basis of herpesvirus entry. Nat Rev Microbiol. 2021;19(2):110-121. https://doi.org/10.1038/s41579-020-00448-w
2. Griffiths P, Reeves M. Pathogenesis of human cytomegalovirus in the immunocompromised host. Nat Rev Microbiol. 2021;19(12):759-773. https://doi.org/10.1038/s41579-021-00582-z
3. Krstanovic F, Britt WJ, Jonjic S, Brizic I. Cytomegalovirus Infection and Inflammation in Developing Brain. Viruses. 2021;13(6):1078. Published 2021 Jun 4. https://doi.org/10.3390/v13061078
4. Griffiths P, Baraniak I, Reeves M. The pathogenesis of human cytomegalovirus. J Pathol. 2015;235(2):288-297. https://doi.org/10.1002/path.4437
5. Acosta E, Bowlin T, Brooks J, et al. Advances in the Development of Therapeutics for Cytomegalovirus Infections. J Infect Dis. 2020;221(Suppl 1):S32-S44. https://doi.org/10.1093/infdis/jiz493
Alternate Names
CMV, CMV glycoprotein B, CMV glycoprotein GP55, Cytomegalovirus glycoprotein GP55, gB, Glycoprotein B, Glycoprotein GP55, HCMV, HCMV glycoprotein B, HCMV glycoprotein GP55, HHV 5 glycoprotein B, HHV 5 glycoprotein GP55, HHV5 glycoprotein B, HHV5 glycoprotein GP55, Human herpesvirus 5 glycoprotein B, Human herpesvirus 5 glycoprotein GP55, UL55
Additional Cytomegalovirus gB Products
Product Documents for Cytomegalovirus gB Antibody [CoraFluor™ 1]
Product Specific Notices for Cytomegalovirus gB Antibody [CoraFluor™ 1]
Sold for research purposes only under agreement from Massachusetts General Hospital, US Patent No. 12,134,721. A license is required for development of new commercial assay platforms (e.g., microarrays, microfluidics), diagnostic use or other unlicensed uses. Please contact Technical Support for further details: techsupport@bio-techne.com.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...